読み込み中
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
前日終値
$54.05
+$2.05 · +3.94%
日中の時刻はETです。市場データは遅延する場合があります。
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
日中レンジ
現在 $54.05
52週レンジ
現在 $54.05
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
61
強気
リスク
53
やや高いリスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
日中レンジ
現在 $54.05
52週レンジ
現在 $54.05
営業利益
純利益
| 指標（CAD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1108.45万 CAD | 118万 CAD | 499.99万 CAD | 1218.09万 CAD | 631.4万 CAD |
| 販売・一般管理 | 256.54万 CAD | 144.56万 CAD | 219.98万 CAD | 255.11万 CAD | 230.91万 CAD |
| 営業費用 | 1393.76万 CAD | 282.28万 CAD | 738.64万 CAD | 1497.51万 CAD | 862.31万 CAD |
| 受取利息 | 151.95万 CAD | 3.01万 CAD | — | — | — |
| 減価償却費と償却費 | 7.69万 CAD | 7.34万 CAD | 7.25万 CAD | 6037 CAD | 862.31万 CAD |
| 営業利益 | −1393.76万 CAD | −282.28万 CAD | −738.64万 CAD | −1497.51万 CAD | −862.31万 CAD |
| 純利益 | −1222.93万 CAD | −280.19万 CAD | −737.22万 CAD | −1496.49万 CAD | −865.08万 CAD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM972.48万0.01%787.4億 USD0.19%$278.94+0.49%
iShares Russell 2000 Growth ETFIWO342.05万0.02%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO305.22万0.02%180億 USD0.06%$112.66+0.50%
Vanguard U.S. Momentum Factor ETFVFMO202.75万0.10%19億 USD0.13%$230.11+1.02%
AdvisorShares Psychedelics ETFPSIL200.08万4.27%4685.29万 USD1.84%$21.765+3.69%
iShares Micro-Cap ETFIWC115.26万0.09%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG58.2万0.03%17億 USD0.06%$260.49+0.91%
State Street SPDR S&P International Small Cap ETFGWX47.26万0.05%9.08億 USD0.40%$45.56+0.93%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard U.S. Momentum Factor ETFVFMOAdvisorShares Psychedelics ETFPSILiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGState Street SPDR S&P International Small Cap ETFGWXAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
